TScan Therapeutics’ (TCRX) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. HC Wainwright currently has a $15.00 price target on the stock. HC Wainwright also issued estimates for TScan Therapeutics’ Q3 2024 earnings at ($0.31) EPS, Q4 2024 earnings at […]
More Stories
Freeport-McMoRan Inc. (NYSE:FCX) Shares Sold by Quantbot Technologies LP
Quantbot Technologies LP trimmed its holdings in Freeport-McMoRan Inc. (NYSE:FCX – Free Report) by 49.2% during the third quarter, according...
Quantbot Technologies LP Has $6.60 Million Holdings in Nutrien Ltd. (NYSE:NTR)
Quantbot Technologies LP increased its holdings in shares of Nutrien Ltd. (NYSE:NTR – Free Report) by 40.0% in the 3rd...
Fox Co. (NASDAQ:FOXA) Shares Purchased by Quantbot Technologies LP
Quantbot Technologies LP raised its stake in shares of Fox Co. (NASDAQ:FOXA – Free Report) by 21.2% in the 3rd...
Dai ichi Life Insurance Company Ltd Has $10.53 Million Holdings in General Electric (NYSE:GE)
Dai ichi Life Insurance Company Ltd decreased its holdings in General Electric (NYSE:GE – Free Report) by 21.5% during the...
The Home Depot, Inc. (NYSE:HD) Shares Purchased by Covington Investment Advisors Inc.
Covington Investment Advisors Inc. raised its position in The Home Depot, Inc. (NYSE:HD – Free Report) by 0.6% during the...
Covington Investment Advisors Inc. Reduces Holdings in Fiserv, Inc. (NYSE:FI)
Covington Investment Advisors Inc. lessened its stake in shares of Fiserv, Inc. (NYSE:FI – Free Report) by 0.6% in the...